Do you want to read an article? Please log in or register.
Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes. A retrospective multicenter comparative effectiveness study
Type 2 Diabetes
Related content
COMMENTED
Type 2 Diabetes
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Lancet.
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A
doi: 10.1016/S0140-6736(18)32260-8.
COMMENTED
Type 2 DiabetesGlycemic Control
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Care
Huthmacher JA, Meier JJ, Nauck MA
doi: 10.2337/dc20-0498
COMMENTED
Type 2 Diabetes
Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetes Obes Metab.
Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Apostolos Tsapas, Bekiari E
doi: 10.1111/dom.14108.
Type 2 Diabetes
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Diabetes Care.
Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR
doi: 10.2337/dc19-1357.
Type 1 DiabetesType 2 DiabetesGlycemic Control
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT)
Diabet Med.
Knudsen ST, Lapolla A, Schultes B, Tentolouris N, Catarig AM, Wolden ML, Siegmund T
doi: 10.1111/dme.13976.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study
Diabetes Obes Metab.
Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J
doi: 10.1111/dom.13266.
Type 2 DiabetesGlycemic Control
Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial
Diabetes Obes Metab.
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, Cardona S, Peng L, Pasquel FJ, Umpierrez GE; Linagliptin Inpatient Research Group
doi: 10.1111/dom.13587.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Lancet Diabetes Endocrinol.
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH
doi: 10.1016/S2213-8587(17)
RECOMMENDED
Type 1 DiabetesType 2 DiabetesPediatric Diabetes
Disordered Eating Behaviors in Youth and Young Adults With Type 1 or Type 2 Diabetes Receiving Insulin Therapy: The SEARCH for Diabetes in Youth Study
Diabetes Care.
Nip ASY, Reboussin BA, Dabelea D, Bellatorre A, Mayer-Davis EJ, Kahkoska AR, Lawrence JM, Peterson CM, Dolan L, Pihoker C, SEARCH for Diabetes in Youth Study Group
doi: 10.2337/dc18-2420.